Pulmolor Tablets No. 10

In stock: 2
$58.00

Ingredients

Active ingredients: ambroxol hydrochloride, loratadine;

1 tablet contains 60 mg of ambroxol hydrochloride and 5 mg of loratadine;

Inactive ingredients: lactose monohydrate, corn starch, microcrystalline cellulose, povidone, magnesium stearate, anhydrous colloidal silicon dioxide, sodium starch glycolate (type A).

Dosage Form

Tablets.

Main physical and chemical properties: flat-cylindrical tablets, almost white in color, with a score line on one side.

Pharmacotherapeutic group

Agents used for coughs and the common cold. Expectorants, excluding combination products containing antitussives.

ATC code R05C.

Pharmacological properties

Pharmacodynamics.

Pulmolor® has a pronounced expectorant effect, soothes and calms a dry cough, eases breathing, normalizes bronchial mucus secretion, improves sputum clearance, reduces inflammation of the respiratory tract, exudate-reducing effect, relieves bronchial smooth muscle spasm and tissue edema, including that of the nasal mucosa, throat, sinuses, and airways; reduces capillary permeability; and alleviates nasal congestion, runny nose, watery eyes, sneezing, itching of the palate and nose, and redness of the eyes.

Ambroxol hydrochloride is a synthetic secretolytic and secretomotor agent. It has a pronounced expectorant effect and a mild antitussive effect. It stimulates the serous cells of the bronchial mucosa, increases the amount of mucous secretion, and thereby restores the disrupted balance between the serous and mucous components. This leads to the normalization of sputum rheological parameters, reducing its viscosity and adhesive properties. It directly stimulates the ciliary activity of the bronchial epithelium, prevents cilia from clumping together, and improves mucociliary clearance of sputum. Ambroxol increases the concentration of surfactant in the lungs and prevents its degradation in pneumocytes. As a mucolytic and expectorant, ambroxol improves respiratory function. The drug reduces bronchial muscle hyperreactivity in patients with asthma. Ambroxol has anti-inflammatory effects and antioxidant properties; it stimulates local immunity and the restoration of the natural surfactant layer. When taking ambroxol, patients’ complaints of cough and phlegm are significantly reduced in proportion to the intensity of treatment. Ambroxol hydrochloride increases the concentration of antibiotics in the lungs and, thus, improves the course of respiratory tract diseases associated with bacterial lung infections.

Loratadine is a selective, long-acting peripheral H1-histamine receptor blocker without central sedative effects. It has an antiallergic effect, relieves bronchial smooth muscle spasms, reduces bronchial sensitivity to histamine, alleviates dry coughs of allergic origin, reduces capillary permeability, reduces tissue edema, runny nose, watery eyes, sneezing, itching of the palate and nose, and redness of the eyes. It prevents the development of and alleviates the course of allergic reactions. Its action occurs through competitive blockade of H1 receptors on effector cells by inhibiting calcium influx into cells, inhibiting histamine release (membrane-stabilizing function), inhibiting eosinophil chemotaxis and their accumulation in the mucous membrane. The antihistamine effect of loratadine begins 1–3 hours after administration, peaks after 8–12 hours, and lasts up to 24 hours. No tolerance has been observed after 28 days of loratadine use.

Indications

Symptomatic treatment of acute and chronic respiratory tract diseases with a spastic and allergic component, associated with impaired bronchial secretion and reduced mucus clearance. Prescribe for acute and chronic bronchitis, chronic obstructive pulmonary disease, pneumonia, and conditions accompanied by bronchial hyperreactivity. In ENT practice, to thin secretions and reduce swelling, it is prescribed for rhinitis, including allergic rhinitis, as part of the comprehensive treatment of sinusitis and otitis.

Contraindications

Hypersensitivity to any component of the drug.

Interactions with Other Medications and Other Types of Interactions

Concomitant use of Pulmolor® with antibiotics is preferable to prescribing antibiotics alone. Pulmolor® increases the concentration of antibiotics in the lungs and, thus, alleviates the course of respiratory tract diseases associated with bacterial lung infections.

This medication should not be taken with alcohol.

Do not take simultaneously with cough suppressants that inhibit mucus clearance.

Potential interactions may occur with all known CYP3A4 or CYP2D6 inhibitors, leading to increased levels of loratadine, which in turn may result in an increased incidence of adverse reactions.

In controlled studies, increased plasma concentrations of loratadine were reported following concomitant use with ketoconazole, erythromycin, and cimetidine; however, these were not accompanied by clinically significant changes (including ECG changes).

Special Considerations for Use

Discontinue the medication 48 hours prior to performing skin tests for reactivity.

There have been isolated reports of severe skin reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), and acute generalized exanthematous pustulosis) that coincided with the use of ambroxol hydrochloride. In most cases, these could be attributed to the severity of the underlying disease in patients and the concomitant use of another medication. Additionally, in the early stages of Stevens-Johnson syndrome or Lyell’s syndrome, patients may experience nonspecific symptoms similar to those of early-stage influenza, such as fever, body aches, rhinitis, cough, and sore throat. These nonspecific, flu-like symptoms may lead to the mistaken use of symptomatic treatments with cough and cold medications. Therefore, if new lesions appear on the skin or mucous membranes, seek medical attention immediately and discontinue treatment with ambroxol hydrochloride.

Since ambroxol may increase mucus secretion, the drug should be used with caution in cases of impaired bronchial motility and increased mucus secretion (for example, in a rare condition such as primary ciliary dyskinesia).

In patients with impaired renal function or severe hepatic insufficiency, the drug should be used with caution (specifically, the dosing interval should be increased or the dose should be reduced). In patients with severe renal insufficiency, accumulation of metabolites formed in the liver is expected.

Excipients.

This medication contains lactose; therefore, patients with known intolerance to certain sugars should consult a doctor before taking this medication.

Use During Pregnancy or Breastfeeding.

Since there is insufficient experience with the use of this medication in pregnant women, it is not recommended for use during pregnancy.

Since the drug passes into breast milk, it is not recommended for use while breastfeeding.

Effect on reaction time when driving or operating machinery.

In general, this medication does not affect reaction time when driving or operating machinery. However, patients should be informed of very rare cases of drowsiness, which may affect the ability to drive or operate machinery.

Dosage and Administration

Adults and children 12 years of age and older should take 1 tablet orally twice daily.

Take after meals with plenty of liquid.

Duration of treatment: up to 14 days. Consult a doctor if symptoms do not subside and/or worsen after 14 days.

Do not use this medication for more than 4–5 days without consulting a doctor.

Children.

Do not use in children under 12 years of age.

Overdose

Symptoms: tachycardia, headache, drowsiness, nausea, vomiting, diarrhea, and decreased blood pressure.

Treatment. In case of overdose, symptomatic and supportive treatment is recommended. Standard measures to remove the drug that has not been absorbed from the stomach are recommended: gastric lavage, administration of crushed activated charcoal with water.

Loratadine is not removed by hemodialysis; it is also unknown whether loratadine is removed by peritoneal dialysis.

After receiving emergency care, the patient should remain under medical supervision.

Side Effects

The drug is generally well tolerated.

Skin: alopecia.

Immune system: hypersensitivity reactions, including rash, hives, itching, anaphylactic reactions (including anaphylactic shock), angioedema; serious skin adverse reactions (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), and acute generalized exanthematous pustulosis).

Nervous system: dysgeusia (taste disturbance), dizziness, seizures, headache, nervousness, fatigue, drowsiness, insomnia.

Gastrointestinal system: nausea, decreased sensation in the mouth, vomiting, diarrhea, dyspepsia, abdominal pain, dry mouth and throat, constipation, hypersalivation, gastritis.

Respiratory system: rhinorrhea, dyspnea (as a symptom of a hypersensitivity reaction).

Hepatobiliary system: liver function abnormalities.

Cardiovascular system: tachycardia, palpitations.

Urinary system: dysuria.

General disorders: fever, weight gain, increased appetite, mucosal reactions.

Shelf life

3 years.

Storage conditions

Store out of reach of children in the original packaging at a temperature not exceeding 25 °C.

Packaging

10 tablets per blister pack; 1 or 2 blister packs per cardboard box.

Dispensing Category

Available without a prescription.

Manufacturer

Sava Health Ltd.

Manufacturer’s location and address of its place of business.

India, GIDC Estate, 507-B-512, Vadhwan City - 363 035, Surendranagar.

Applicant

Movi Health GmbH.

Applicant’s location.

Blegi Strasse 25, 6340 Baar, Switzerland.